Knockout of ykcB, a Putative Glycosyltransferase, Leads to Reduced Susceptibility to Vancomycin in Bacillus subtilis

Although vancomycin is effective against Gram-positive bacteria, vancomycin-resistant bacteria are a major public health concern. While the vancomycin-resistance mechanisms of clinically important bacteria such as Staphylococcus aureus, Enterococcus faecium, and Streptococcus pneumoniae are well studied, they remain unclear in other Gram-positive bacteria. ABSTRACT Vancomycin resistance of Gram-positive bacteria poses a serious health concern around the world. In this study, we searched for vancomycin-tolerant mutants from a gene deletion library of a model Gram-positive bacterium, Bacillus subtilis, to elucidate the mechanism of vancomycin resistance. We found that knockout of ykcB, a glycosyltransferase that is expected to utilize C55-P-glucose to glycosylate cell surface components, caused reduced susceptibility to vancomycin in B. subtilis. Knockout of ykcB altered the susceptibility to multiple antibiotics, including sensitization to β-lactams and increased the pathogenicity to silkworms. Furthermore, the ykcB-knockout mutant had (i) a decreased amount of lipoteichoic acid, (ii) decreased biofilm formation, and (iii) an increased content of diglucosyl diacylglycerol, a glycolipid that shares a precursor with C55-P-glucose. These phenotypes and vancomycin tolerance were abolished by knockout of ykcC, a gene in the same operon with ykcB probably involved in C55-P-glucose synthesis. Overexpression of ykcC enhanced vancomycin tolerance in both the parent strain and the ykcB-knockout mutant. These findings suggest that ykcB deficiency induces structural changes of cell surface molecules depending on the ykcC function, leading to reduced susceptibility to vancomycin, decreased biofilm formation, and increased pathogenicity to silkworms. IMPORTANCE Although vancomycin is effective against Gram-positive bacteria, vancomycin-resistant bacteria are a major public health concern. While the vancomycin-resistance mechanisms of clinically important bacteria such as Staphylococcus aureus, Enterococcus faecium, and Streptococcus pneumoniae are well studied, they remain unclear in other Gram-positive bacteria. In the present study, we searched for vancomycin-tolerant mutants from a gene deletion library of a model Gram-positive bacterium, Bacillus subtilis, and found that knockout of a putative glycosyltransferase, ykcB, caused vancomycin tolerance in B. subtilis. Notably, unlike the previously reported vancomycin-resistant bacterial strains, ykcB-deficient B. subtilis exhibited increased virulence while maintaining its growth rate. Our results broaden the fundamental understanding of vancomycin-resistance mechanisms in Gram-positive bacteria.

[1]  C. Kaito,et al.  Knockout of mlaA increases Escherichia coli virulence in a silkworm infection model , 2022, PloS one.

[2]  T. Fujiwara,et al.  The Absence of Osmoregulated Periplasmic Glucan Confers Antimicrobial Resistance and Increases Virulence in Escherichia coli , 2021, Journal of Bacteriology.

[3]  P. Freemont,et al.  Bacillus subtilis YngB contributes to wall teichoic acid glucosylation and glycolipid formation during anaerobic growth , 2020, bioRxiv.

[4]  C. Kaito,et al.  Animal infection models using non‐mammals , 2020, Microbiology and immunology.

[5]  R. Karaman,et al.  Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches , 2020, Molecules.

[6]  D. Fish,et al.  The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections , 2020, Antimicrobial Agents and Chemotherapy.

[7]  Tetsuya Hayashi,et al.  Non-pathogenic Escherichia coli acquires virulence by mutating a growth-essential LPS transporter , 2020, PLoS pathogens.

[8]  S. Salipante,et al.  Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels. , 2020, The Journal of antimicrobial chemotherapy.

[9]  M. Loessner,et al.  GtcA is required for LTA glycosylation in Listeria monocytogenes serovar 1/2a and Bacillus subtilis , 2019, bioRxiv.

[10]  W. Vollmer,et al.  Inactivation of the Monofunctional Peptidoglycan Glycosyltransferase SgtB Allows Staphylococcus aureus To Survive in the Absence of Lipoteichoic Acid , 2018, bioRxiv.

[11]  A. Gründling,et al.  Discovery of genes required for lipoteichoic acid glycosylation predicts two distinct mechanisms for wall teichoic acid glycosylation , 2018, The Journal of Biological Chemistry.

[12]  W. Rose,et al.  Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus , 2017, Antimicrobial Agents and Chemotherapy.

[13]  M. Cancino-Diaz,et al.  Staphylococcus epidermidis lipoteichoic acid: exocellular release and ltaS gene expression in clinical and commensal isolates , 2017, Journal of medical microbiology.

[14]  C. Gross,et al.  Construction and Analysis of Two Genome-Scale Deletion Libraries for Bacillus subtilis. , 2017, Cell systems.

[15]  Eleni Karinou,et al.  Identification of a Lipoteichoic Acid Glycosyltransferase Enzyme Reveals that GW-Domain-Containing Proteins Can Be Retained in the Cell Wall of Listeria monocytogenes in the Absence of Lipoteichoic Acid or Its Modifications , 2016, Journal of bacteriology.

[16]  T. Aoyagi,et al.  Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis , 2015, Scientific Reports.

[17]  A. Tomasz,et al.  Mechanisms of vancomycin resistance in Staphylococcus aureus. , 2014, The Journal of clinical investigation.

[18]  M. Rybak,et al.  Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": Taking advantage of the back door left open? , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[19]  G. Kaatz,et al.  Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model: Exploring the “Seesaw Effect” , 2013, Antimicrobial Agents and Chemotherapy.

[20]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[21]  D. Ward,et al.  Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. , 2012, The Journal of infectious diseases.

[22]  J. Errington,et al.  A widespread family of bacterial cell wall assembly proteins , 2011, The EMBO journal.

[23]  Torsten Seemann,et al.  Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR , 2011, PLoS pathogens.

[24]  L. Cui,et al.  Mutation of RNA Polymerase β Subunit (rpoB) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3 , 2011, Antimicrobial Agents and Chemotherapy.

[25]  L. Cui,et al.  walK and clpP Mutations Confer Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.

[26]  M. Ogura,et al.  Identification of the sequences recognized by the Bacillus subtilis response regulator YclJ , 2010, Archives of Microbiology.

[27]  T. Awasaki,et al.  Identification of Lipoteichoic Acid as a Ligand for Draper in the Phagocytosis of Staphylococcus aureus by Drosophila Hemocytes1 , 2009, The Journal of Immunology.

[28]  S. McAllister,et al.  Accuracy of Commercial and Reference Susceptibility Testing Methods for Detecting Vancomycin-Intermediate Staphylococcus aureus , 2009, Journal of Clinical Microbiology.

[29]  G. Eliopoulos,et al.  Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. , 2009, The Journal of infectious diseases.

[30]  L. Cui,et al.  Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[31]  M. Ogura,et al.  Identification of the Sequences Recognized by the Bacillus subtilis Response Regulator YrkP , 2008, Bioscience, biotechnology, and biochemistry.

[32]  T. Kohler,et al.  A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity , 2007, Molecular microbiology.

[33]  Benjamin P. Howden,et al.  Isolates with Low-Level Vancomycin Resistance Associated with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia , 2006, Antimicrobial Agents and Chemotherapy.

[34]  S. Hamada,et al.  Silkworm pathogenic bacteria infection model for identification of novel virulence genes , 2005, Molecular microbiology.

[35]  G. Bierbaum,et al.  Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin , 2003, Antimicrobial Agents and Chemotherapy.

[36]  Haruo Watanabe,et al.  Silkworm larvae as an animal model of bacterial infection pathogenic to humans. , 2002, Microbial pathogenesis.

[37]  J. Costerton,et al.  Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms , 2002, Clinical Microbiology Reviews.

[38]  R. Jayaswal,et al.  Characterization of Passage-Selected Vancomycin-Resistant Staphylococcus aureus Strains of Diverse Parental Backgrounds , 2000, Antimicrobial Agents and Chemotherapy.

[39]  C. Walsh,et al.  VanX, a bacterial D-alanyl-D-alanine dipeptidase: resistance, immunity, or survival function? , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Tomasz,et al.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.

[41]  A. Tomasz,et al.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus , 1997, Journal of bacteriology.

[42]  Y. Sadaie,et al.  Formation of competent Bacillus subtilis cells , 1983, Journal of bacteriology.

[43]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[44]  橋本 優実 Identification of lipoteichoic acid as a ligand for Draper in the phagocytosis of Staphylococcus aureus by Drosophila hemocytes , 2010 .